Elan Streamlines CNS Portfolio with Divestment of Two Drugs
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 47 (Table of Contents)
Published: 4 May-2004
DOI: 10.3833/pdr.v2004.i47.813 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Elan entered into agreement with Vernalis and Eisai to divest two of its potential neurological candidates. Vernalis reacquired its North American rights to Frova™ (frovatriptan), for treating migraine. The deal could be worth up to US$55 M to Elan. Elan has also divested the North American, European and Mexican marketing rights to Eisai for Zonegran®, for treating epilepsy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS